Kenvue Inc. $KVUE Shares Bought by American Century Companies Inc.

American Century Companies Inc. lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 22.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,046,660 shares of the company’s stock after buying an additional 6,781,640 shares during the period. Kenvue makes up 0.3% of American Century Companies Inc.’s holdings, making the stock its 29th biggest position. American Century Companies Inc.’s holdings in Kenvue were worth $601,267,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Kenvue in the second quarter valued at approximately $537,418,000. Independent Franchise Partners LLP grew its holdings in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after buying an additional 21,886,537 shares in the last quarter. Amundi increased its stake in shares of Kenvue by 82.5% in the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock worth $305,446,000 after acquiring an additional 6,559,261 shares during the last quarter. Mondrian Investment Partners LTD acquired a new stake in shares of Kenvue in the 3rd quarter worth $79,269,000. Finally, Vanguard Group Inc. raised its holdings in shares of Kenvue by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after acquiring an additional 4,101,880 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.6%

NYSE KVUE opened at $19.11 on Friday. The firm’s fifty day moving average price is $17.72 and its 200 day moving average price is $17.56. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.69. The company has a market capitalization of $36.62 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 4.35 and a beta of 0.59.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The business had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on KVUE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Barclays upped their price objective on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Citigroup increased their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Finally, UBS Group raised their target price on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $19.50.

Insiders Place Their Bets

In other news, Director Jeffrey C. Smith purchased 3,200,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.68% of the stock is currently owned by company insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.